Centre of Research Excellence in
Pulmonary Fibrosis
PACT PF Australasian Clinical Trials

PACT – New Clinical Trial and Research

Trial title	A Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to determine the safety, tolerability, immunogenicity and pharmacokinetic properties of LASN01 in healthy subjects and in patients with idiopathic pulmonary fibrosis or thyroid eye disease.
Trial synopsis	This project is testing the safety, tolerability (if any side effects occur), pharmacokinetics (PK, the amount of study drug in your blood), immunogenicity (if your body makes antibodies against LASN01) and pharmacodynamics (PD, the effect of the study drug on your body) of a single and multiple doses of a new drug called LASN01. Lassen Therapeutics is developing the study drug LASN01 as a potential new treatment for IPF and PF-ILD. LASN01 is an antibody medication that is directed against a human protein called IL-11 receptor. IL-11 receptor is believed to be the starting point of the complex cellular process that eventually leads to the fibrosis in the lung. By blocking the IL-11 receptor, it is believed that LASN01 can prevent the progress of and alleviate PF- ILD symptoms.
Investigational medicinal product, comparator and randomisation	LASN01 or placebo (approximately 3:1 randomization to active treatment versus placebo).
Disease target	IPF, PF-ILD
Sponsor	Lassen Therapeutics 1
Duration	18 weeks
Trial Status	Recruiting
Trial phase	Phase I
Key inclusion criteria	As above
Key exclusion criteria	As above
Number of participants sought	8-12
Lead site(s) in Australia	Nucleus Network Melbourne
Lead site(s) in New Zealand	N/A
Additional sites	Nucleus Network Brisbane
Contact	naomi.derrick@sydney.edu.au